DPP-4 Therapy Center

We know from previous studies that obesity and type 2 diabetes are associated with vascular stiffening and the development of cardiovascular disease.

A DPP-4 inhibitor can help to prevent kidney function and did not have any negative cardiovascular effects.

DPP-4 Inhibitors offer some advantages over existing oral options for the management of type 2 diabetes such as a negligible risk of hypoglycemia compared with sulfonylureas and, in general, a weight-neutral profile.

Forms, dosages and dosing considerations for pregnancy, breastfeeding, hepatic and renal.

Data from 2 trials show long-term use can improve albumin/creatinine ratio, but not other renal outcomes.

Initiation of glucagon like peptide-1 agonists may increase risk of gallbladder or bile duct disease and cholecystectomy; no increased risk associated with DPP-4 inhibitor therapy.

Can DPP-4 inhibitors and GLP-1 analogues cause bile duct and gallbladder complications?

Alogliptin is efficient and safe in the management of type 2 diabetes even in patients who have cardiovascular disease as a comorbidity.

Large observational study using real-world data finds no increased risk for hospitalized heart failure (hHF) among patients who initiated use of DPP-4 inhibitors, compared to other antihyperglycemics.

Reduce the dose of sulphonylureas when adding DPP-4 inhibitor treatment in patients with type 2 diabetes, study warns.